Advertisement

Heart and Vessels

, Volume 34, Issue 4, pp 641–649 | Cite as

The relationship between serum indoxyl sulfate and the renal function after catheter ablation of atrial fibrillation in patients with mild renal dysfunction

  • Hideki Koike
  • Toshisuke MoritaEmail author
  • Junko Tatebe
  • Ippei Watanabe
  • Makiko Koike
  • Shintaro Yao
  • Masaya Shinohara
  • Hitomi Yuzawa
  • Takeya Suzuki
  • Tadashi Fujino
  • Takanori Ikeda
Original Article
  • 133 Downloads

Abstract

Indoxyl sulfate (IS), a protein-bound uremic toxin, induces renal disorders and atrial fibrillation (AF). It is well known that renal dysfunction is a risk factor for AF and radiofrequency catheter ablation (RFCA) improves the renal function. However, the improvement in the renal function after RFCA in patients with early stage chronic kidney disease (CKD) and the serial changes in the IS level have not been fully elucidated. This study aimed to investigate whether IS affects the improvement in the renal function. A total of 91 consecutive patients with mild kidney dysfunction (CKD stage I–II) who underwent RFCA and maintained sinus rhythm were prospectively enrolled. The plasma IS level and estimated glomerular filtration rate (eGFR) were determined before, 3 months, and 1 year after RFCA. The patients were divided according to the IS quartiles (Q1–4; < 0.4, 0.4–0.7, 0.7–1.2, and > 1.2 μg/ml). There was no significant difference in the eGFR among the IS quartiles. A significantly higher eGFR improvement rate was obtained for IS-Q4 than the other quartiles (p = 0.039). The IS-Q4 IS level significantly decreased at 1 year after RFCA (1.8 ± 0.8 to 1.2 ± 0.7 μg/ml, p < 0.01). The multivariable logistic model revealed that a high-IS level (IS-Q4) was an independent predictor of an eGFR improvement (OR 3.33; 95% CI 1.16–9.59; p = 0.026). A high-IS level reduction after RFCA improved the renal function in AF patients with mild kidney dysfunction.

Keywords

Indoxyl sulfate Atrial fibrillation Renal function Catheter ablation 

Notes

Acknowledgments

This manuscript was supported in part by Grants-in-Aid (15K09103 and 16K01433 to T.I.) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank Mr. John Martin for his help with the preparation of the manuscript and Mr. Osuka for his help in supporting this present study.

Compliance with ethical standards

Conflict of interest

This research received no grants from any funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that there is no conflict of interest.

References

  1. 1.
    Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, Lerma EV (2010) Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 5:173–181CrossRefGoogle Scholar
  2. 2.
    Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S, Kawano Y (2010) Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 28:1738–1744CrossRefGoogle Scholar
  3. 3.
    Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, Uemura J, Shibazaki K (2008) Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 102:1056–1059CrossRefGoogle Scholar
  4. 4.
    Navaravong L, Barakat M, Burgon N, Mahnkopf C, Koopmann M, Ranjan R, Kholmovski E, Marrouche N, Akoum N (2015) Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 26:21–27CrossRefGoogle Scholar
  5. 5.
    Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI, Chronic Renal Insufficiency Cohort (CRIC) Study Group (2010) Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC). Am Heart J 159:1102–1107CrossRefGoogle Scholar
  6. 6.
    Takahashi Y, Takahashi A, Kuwahara T, Okubo K, Fujino T, Takagi K, Nakashima E, Kamiishi T, Hikita H, Hirao K, Isobe M (2011) Renal function after catheter ablation of atrial fibrillation. Circulation 124:2380–2387CrossRefGoogle Scholar
  7. 7.
    Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y (2009) Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158:629–636CrossRefGoogle Scholar
  8. 8.
    Yoshikawa D, Ishii H, Suzuki S, Takeshita K, Kumagai S, Hayashi M, Niwa T, Izawa H, Murohara T (2014) Plasma indoxyl sulfate and estimated glomerular filtration rate. Circ J 78:2477–2482CrossRefGoogle Scholar
  9. 9.
    Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox) (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4:1551–1558CrossRefGoogle Scholar
  10. 10.
    Niwa T, Takeda N, Tatematsu A, Maeda K (1988) Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34:2264–2267Google Scholar
  11. 11.
    Aoki K, Teshima Y, Kondo H, Saito S, Fukui A, Fukunaga N, Nawata T, Shimada T, Takahashi N, Shibata H (2015) Role of indoxyl sulfate as a predisposing factor for atrial fibrillation in renal dysfunction. J Am Heart Assoc 4:e002023CrossRefGoogle Scholar
  12. 12.
    Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, Kelly DJ, Krum H (2012) Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 7:e41281CrossRefGoogle Scholar
  13. 13.
    Niwa T, Ise M (1994) Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124:96–104Google Scholar
  14. 14.
    Shimazu S, Hirashiki A, Okumura T, Yamada T, Okamoto R, Shinoda N, Takeshita K, Kondo T, Niwa T, Murohara T (2013) Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J 77:390–396CrossRefGoogle Scholar
  15. 15.
    Sun CY, Hsu HH, Wu MS (2013) p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 28:70–78CrossRefGoogle Scholar
  16. 16.
    Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 17:1444–1452CrossRefGoogle Scholar
  17. 17.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609–1678CrossRefGoogle Scholar
  18. 18.
    Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452–458CrossRefGoogle Scholar
  19. 19.
    Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50:2021–2028CrossRefGoogle Scholar
  20. 20.
    Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P (2007) The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5:1302–1308CrossRefGoogle Scholar
  21. 21.
    Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, Hashimoto M, Fukunaga E, Maruyama T, Otagiri M (2007) An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 24:1283–1289CrossRefGoogle Scholar
  22. 22.
    Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J (2005) Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112:1266–1273CrossRefGoogle Scholar
  23. 23.
    Chen WT, Chen YC, Hsieh MH, Huang SY, Kao YH, Chen YA, Lin YK, Chen SA, Chen YJ (2015) The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis. J Cardiovasc Electrophysiol 26:203–210CrossRefGoogle Scholar
  24. 24.
    Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, Takayama F, Aoyama I, Nakamura S, Endou H, Niwa T (2002) Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 13:1711–1720CrossRefGoogle Scholar
  25. 25.
    Huc T, Nowinski A, Drapala A, Konopelski P, Ufnal M (2018) Indole and indoxyl sulfate, gut bacteria metabolites of tryptophan, change arterial blood pressure via peripheral and central mechanisms in rats. Pharmacol Res 130:172–179CrossRefGoogle Scholar
  26. 26.
    Konopelski P, Ufnal M (2018) Indoles—gut bacteria metabolites of tryptophan with pharmacotherapeutic potential. Curr Drug Metab.  https://doi.org/10.2174/1389200219666180427164731 Google Scholar
  27. 27.
    Providencia R, Fernandes A, Paiva L, Faustino A, Barra S, Botelho A, Trigo J, Nascimento J, Leitao-Marques A (2013) Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology 124:3–10CrossRefGoogle Scholar
  28. 28.
    Muellerleile K, Groth M, Steven D, Hoffmann BA, Saring D, Radunski UK, Lund GK, Adam G, Rostock T, Willems S (2013) Cardiovascular magnetic resonance demonstrates reversible atrial dysfunction after catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol 24:762–767CrossRefGoogle Scholar
  29. 29.
    Machino-Ohtsuka T, Seo Y, Ishizu T, Yanaka S, Nakajima H, Atsumi A, Yamamoto M, Kawamura R, Koshino Y, Machino T, Kuroki K, Yamasaki H, Igarashi M, Sekiguchi Y, Tada H, Aonuma K (2013) Significant improvement of left atrial and left atrial appendage function after catheter ablation for persistent atrial fibrillation. Circ J 77:1695–1704CrossRefGoogle Scholar
  30. 30.
    La Meir M, Gelsomino S, Luca F, Pison L, Rao CM, Wellens F, Maessen JG (2013) Improvement of left atrial function and left atrial reverse remodeling after minimally invasive radiofrequency ablation evaluated by 2-dimensional speckle tracking echocardiography. J Thorac Cardiovasc Surg 146:72–77CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Hideki Koike
    • 1
  • Toshisuke Morita
    • 2
    Email author
  • Junko Tatebe
    • 2
  • Ippei Watanabe
    • 1
  • Makiko Koike
    • 1
  • Shintaro Yao
    • 1
  • Masaya Shinohara
    • 1
  • Hitomi Yuzawa
    • 1
  • Takeya Suzuki
    • 1
  • Tadashi Fujino
    • 1
  • Takanori Ikeda
    • 1
  1. 1.Department of Cardiovascular MedicineToho University Faculty of MedicineTokyoJapan
  2. 2.Department of Laboratory MedicineToho University Faculty of MedicineTokyoJapan

Personalised recommendations